Sehmisch, Stephan

[["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.journal","Molecular Therapy - Nucleic Acids"],["dc.bibliographiccitation.lastpage","452"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hoffmann, Daniel B."],["dc.contributor.author","Gruber, Jens"],["dc.contributor.author","Böker, Kai O."],["dc.contributor.author","Deppe, Delia"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Schilling, Arndt F."],["dc.contributor.author","Lemus-Diaz, Nicolas"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Schneider, Stefan"],["dc.date.accessioned","2019-07-09T11:45:51Z"],["dc.date.available","2019-07-09T11:45:51Z"],["dc.date.issued","2018"],["dc.description.abstract","Rebalancing of the RANKL/OPG system seems to be an effective treatment strategy in postmenopausal osteoporosis. Here, we evaluate the knockdown of RANKL by in-vivo-delivered siRNA in a rat model of osteoporosis. Virus-like-particles (VLPs) derived from polyoma JC virus were used for delivering RANKL siRNA in ovariectomized (OVX) rats. 48 rats were ovariectomized and treated with either 17β-estradiol (E2), VLPs containing RANKL siRNA (siRANKL), or VLPs containing non-cognate siRNA (siCtrl). All OVX groups were subdivided into the prophylaxis group (PG) and the therapy group (TG). The PG received treatment directly after being OVX for 10 weeks. The TG received treatment 5 weeks after being OVX for 5 weeks. Rats were sacrificed 10 weeks after being OVX. Bone and blood samples were analyzed. E2 and siRANKL showed a significant knockdown of RANKL mRNA. A protein knockdown was observed with E2 and siRANKL in the TG but not in the PG. No distinct improvements in biomechanical and morphological properties of the bones were observed after siRANKL treatment. In the PG, E2 protected the bone structure. We demonstrated successful mRNA and protein knockdown by VLP-mediated RNAi in vivo. Knockdown of membranous RANKL did not result in significant improvements of bone properties in this model of early-stage postmenopausal osteoporosis."],["dc.identifier.doi","10.1016/j.omtn.2018.06.001"],["dc.identifier.pmid","30195781"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15329"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59322"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2162-2531"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Effects of RANKL Knockdown by Virus-like Particle-Mediated RNAi in a Rat Model of Osteoporosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","705"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Calcified Tissue International"],["dc.bibliographiccitation.lastpage","719"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Saul, D."],["dc.contributor.author","Harlas, B."],["dc.contributor.author","Ahrabi, A."],["dc.contributor.author","Kosinsky, R. L."],["dc.contributor.author","Hoffmann, D. B."],["dc.contributor.author","Wassmann, M."],["dc.contributor.author","Wigger, R."],["dc.contributor.author","Böker, K. O."],["dc.contributor.author","Sehmisch, S."],["dc.contributor.author","Komrakova, M."],["dc.date.accessioned","2020-06-10T14:22:48Z"],["dc.date.available","2020-06-10T14:22:48Z"],["dc.date.issued","2017"],["dc.description.abstract","Osteoporosis is often accompanied by sarcopenia. The effect of strontium ranelate (SR) on muscle tissue has not been investigated sufficiently. In this study, the effect of different SR treatments on muscle was studied. Additionally, the lumbar vertebrae were analyzed. Three-month-old female rats were divided into five groups (n = 12): Group 1: untreated (NON-OVX); Group 2: ovariectomized and left untreated (OVX); Group 3: SR after OVX until the study ended (13 weeks, SR prophylaxis and therapy = pr+th); Group 4: OVX and SR for 8 weeks (SR prophylaxis = pr); Group 5: SR for 5 weeks from the 8 week after OVX (SR therapy = SR th). SR was applied in food (630 mg/kg body weight). The size of muscle fibers, capillary density, metabolic enzymes, and mRNA expression were assessed in soleus, gastrocnemius, and longissimus muscles. The vertebral bodies underwent micro-CT, biomechanical, and ashing analyses. In general, SR did not alter the muscle histological parameters. The changes in fiber size and capillary ratio were related to the body weight. Myostatin mRNA was decreased in Sr pr+th; protein expression was not changed. SR th led to increase in mRNA expression of vascular endothelial growth factor (Vegf-B). In lumbar spine, SR pr+th enhanced biomechanical properties, bone mineral density, trabecular area, density, and thickness and cortical density. The reduced calcium/phosphate ratio in the SR pr+th group indicates the replacement of calcium by strontium ions. SR has no adverse effects on muscle tissue and it shows a favorable time-dependent effect on vertebrae. A functional analysis of muscles could verify these findings."],["dc.identifier.doi","10.1007/s00223-017-0374-0"],["dc.identifier.pmid","29242963"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66222"],["dc.language.iso","en"],["dc.relation.eissn","1432-0827"],["dc.relation.issn","0171-967X"],["dc.title","Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","850"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Planta Medica"],["dc.bibliographiccitation.lastpage","857"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Kolios, Leila"],["dc.contributor.author","Schumann, Jacob"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Rack, Thomas"],["dc.contributor.author","Tezval, Mohammed"],["dc.contributor.author","Seidlova-Wuttke, Dana"],["dc.contributor.author","Frosch, Karl-Heinz"],["dc.contributor.author","Stuermer, Klaus Michael"],["dc.contributor.author","Stuermer, Ewa Klara"],["dc.date.accessioned","2018-11-07T08:43:01Z"],["dc.date.available","2018-11-07T08:43:01Z"],["dc.date.issued","2010"],["dc.description.abstract","Osteoporosis and its accompanying, predominantly metaphyseal, fractures are a major health problem. Black cohosh (Cimicifuga racemosa) and estrogen positively influence osteoporotic bone. Both substances may improve fracture healing in early osteoporosis as well. In 48 twelve-week-old ovariectomized or, respectively, sham-operated (SHAM) rats, a standardized metaphyseal tibia osteotomy with bridging T-plate fixation was performed. During the healing process of 35 days, rats received soy-free (SHAM, osteopenic C), estrogen-(E) or Cimicifuga racemosa-(CR) supplemented diets. After sacrifice, the callus formation was analyzed with regard to biomechanical quality, morphology, quantity, time course of new bone built and gene expression. CR induced a high rate of metaphyseal callus formation. The biomechanical properties and the amount of new callus formation indicated that fracture healing was still in progress. Therefore, gene expression of osteoblasts was comparatively high. Body weight and the trabecular structure were influenced little by CR. Estrogen improved the biomechanical properties of the callus. Resistance to microfracturing was significantly enhanced in the E group and even superior to SHAM. Remodeling of the callus formation had already begun. The trabecular network and the typical endosteal fracture healing were especially improved. Osteoporotic metaphyseal fracture healing was improved by estrogen more than by Cimicifuga racemosa. The process of fracture healing occurred nearly physiologically. The generation of callus formation was supported by Cimicifuga racemosa as well, but the five-week duration of application was too short for Cimicifuga racemosa to show its complete potential. Already-initiated Cimicifuga racemosa therapy for menopausal symptoms could be continued during fracture healing without hesitation."],["dc.description.sponsorship","DFG [STU 478/2-1]"],["dc.identifier.doi","10.1055/s-0029-1240798"],["dc.identifier.isi","000279668400002"],["dc.identifier.pmid","20104444"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19846"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0032-0943"],["dc.title","Effects of Black Cohosh (Cimicifuga racemosa) and Estrogen on Metaphyseal Fracture Healing in the Early Stage of Osteoporosis in Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","301"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Operative Orthopädie und Traumatologie"],["dc.bibliographiccitation.lastpage","310"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Viezens, L."],["dc.contributor.author","Sehmisch, S."],["dc.contributor.author","Lehmann, W."],["dc.contributor.author","Weiser, L."],["dc.date.accessioned","2020-12-10T14:08:03Z"],["dc.date.available","2020-12-10T14:08:03Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00064-019-0609-5"],["dc.identifier.eissn","1439-0981"],["dc.identifier.issn","0934-6694"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16565"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70360"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Pedikelsubtraktionsosteotomie zur Korrektur rigider Deformitäten"],["dc.title.alternative","Pedicle subtraction osteotomy to correct rigid deformities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","187"],["dc.bibliographiccitation.journal","Bone"],["dc.bibliographiccitation.lastpage","194"],["dc.bibliographiccitation.volume","64"],["dc.contributor.author","Stuermer, Ewa Klara"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Dullin, Christian"],["dc.contributor.author","Schaefer, Nadine"],["dc.contributor.author","Hallecker, Jan"],["dc.contributor.author","Stuermer, Klaus-Michael"],["dc.date.accessioned","2018-11-07T09:38:39Z"],["dc.date.available","2018-11-07T09:38:39Z"],["dc.date.issued","2014"],["dc.description.abstract","Current osteoporosis therapies aim to delay bone destruction and have additional anabolic effects. While they have demonstrated some positive effects on bone healing, more progress is needed in this area. This study used the well-known osteoporotic agents estrogen (E) and raloxifene (R) in conjunction with biomechanical whole body vibration (WBV) at a frequency of 70 Hz twice daily for six weeks to stimulate bone healing. Eighty-four 3-month old female Sprague-Dawley rats (12 per group) were bilaterally ovariectomized to develop osteopenia within eight weeks. Osteotomy of the metaphyseal tibiae was performed and fracture healing was then studied using mechanical tests, histomorphometry, computed tomography (mu CT), and gene analysis. We found that E and R improved the structure of osteopenic bones as did WBV alone, although significant levels for WBV were seldom reached. Combination treatments significantly enhanced stiffness (R + WBV; p < 0.05), endosteal bone (R + WBV; p < 0.01), and trabecular density (E + WBV; p < 0.05, R + WBV; p < 0.05). In addition, the expression of osteoclast-specific Trap was significantly reduced after treatment with E, R, or their combination with WBV (p < 0.01). The effects were additive and not inhibitory, leading us to conclude that the combined applications of WBV with E or R may improve the healing of osteopenic bones. The therapies studied are all currently approved for human use, suggesting ready applicability to clinical practice. To better understand the effects of WBV on osteopenic bones, the ideal vibration regime will require further study. (C) 2014 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","German Research Foundation (DFG) [STU 478/3-1]"],["dc.identifier.doi","10.1016/j.bone.2014.04.008"],["dc.identifier.isi","337011500026"],["dc.identifier.pmid","24735975"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33112"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1873-2763"],["dc.relation.issn","8756-3282"],["dc.title","Whole body vibration during fracture healing intensifies the effects of estradiol and raloxifene in estrogen-deficient rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","408"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Calcified Tissue International"],["dc.bibliographiccitation.lastpage","422"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Hoffmann, D. B."],["dc.contributor.author","Nuehnen, V."],["dc.contributor.author","Stueber, H."],["dc.contributor.author","Wassmann, M."],["dc.contributor.author","Wicke, Michael"],["dc.contributor.author","Tezval, Mohammed"],["dc.contributor.author","Stuermer, Klaus-Michael"],["dc.contributor.author","Sehmisch, Stefan"],["dc.date.accessioned","2018-11-07T10:08:11Z"],["dc.date.available","2018-11-07T10:08:11Z"],["dc.date.issued","2016"],["dc.description.abstract","The aim of the present study was to study the effect of combined therapy of teriparatide (PTH) or strontium ranelate (SR) with whole-body vibration (WBV) on bone healing and muscle properties in an osteopenic rat model. Seventy-two rats (3 months old) were bilaterally ovariectomized (Ovx), and 12 rats were left intact (Non-Ovx). After 8 weeks, bilateral transverse osteotomy was performed at the tibia metaphysis in all rats. Thereafter, Ovx rats were divided into six groups (n = 12): (1) Ovx-no treatment, (2) Ovx + vibration (Vib), (3) SR, (4) SR + Vib, (5) PTH, and (6) PTH + Vib. PTH (40 mu g/kg BW sc. 5x/week) and SR (613 mg/kg BW in food daily) were applied on the day of ovariectomy, vibration treatments 5 days later (vertical, 70 Hz, 0.5 mm, 2x/day for 15 min) for up to 6 weeks. In the WBV + SR group, the callus density, trabecular number, and Alp and Oc gene expression were decreased compared to SR alone. In the WBV + PTH group, the cortical and callus widths, biomechanical properties, Opg gene expression, and Opg/Rankl ratio were increased; the cortical and callus densities were decreased compared to PTH alone. A case of non-bridging was found in both vibrated groups. Vibration alone did not change the bone parameters; PTH possessed a stronger effect than SR therapy. In muscles, combined therapies improved the fiber size of Ovx rats. WBV could be applied alone or in combination with anti-osteoporosis drug therapy to improve muscle tissue. However, in patients with fractures, anti-osteoporosis treatments and the application of vibration could have an adverse effect on bone healing."],["dc.description.sponsorship","German Research Foundation (DFG) [SE 1966/5-1]"],["dc.identifier.doi","10.1007/s00223-016-0156-0"],["dc.identifier.isi","000382633200009"],["dc.identifier.pmid","27272029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39422"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0827"],["dc.relation.issn","0171-967X"],["dc.title","The Effect of Vibration Treatments Combined with Teriparatide or Strontium Ranelate on Bone Healing and Muscle in Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Endocrinological Investigation"],["dc.contributor.author","Komrakova, M."],["dc.contributor.author","Büchler, G."],["dc.contributor.author","Böker, K. O."],["dc.contributor.author","Lehmann, W."],["dc.contributor.author","Schilling, A. F."],["dc.contributor.author","Roch, P. J."],["dc.contributor.author","Taudien, S."],["dc.contributor.author","Hoffmann, D. B."],["dc.contributor.author","Sehmisch, S."],["dc.date.accessioned","2022-09-01T09:49:26Z"],["dc.date.available","2022-09-01T09:49:26Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Purpose\n Enobosarm (EN), a selective androgen receptor modulator and raloxifene (RAL), a selective estrogen receptor modulator, have been shown to improve bone tissue in osteoporotic males. The present study evaluated the effects of a combination therapy of EN and RAL on bone properties in orchiectomized rats compared to the respective single treatments.\n \n \n Methods\n Eight-month-old male Sprague–Dawley rats were either left intact (Non-Orx) or orchiectomized (Orx). The Orx rats were divided into four groups (n = 15 each): 1) Orx, 2) EN treatment (Orx + EN), 3) RAL treatment (Orx + RAL), 4) combined treatment (Orx + EN + RAL). EN and RAL (0.4 mg and 7 mg/kg body weight/day) were applied immediately after Orx with a soy-free pelleted diet for up to 18 weeks. The lumbar spine and femora were examined by micro-CT, biomechanical, histomorphological, ashing, and gene expression analyses.\n \n \n Results\n EN exhibited an anabolic effect on bone, improving some of its parameters in Orx rats, but did not affect biomechanical properties. RAL exhibited antiresorptive activity, maintaining the biomechanical and trabecular parameters of Orx rats at the levels of Non-Orx rats. EN + RAL exerted a stronger effect than the single treatments, improving most of the bone parameters. Liver weight increased after all treatments; the kidney, prostate, and levator ani muscle weights increased after EN and EN + RAL treatments. BW was reduced due to a decreased food intake in the Orx + RAL group and due a reduced visceral fat weight in the Orx + EN + RAL group.\n \n \n Conclusion\n The EN + RAL treatment appeared to be promising in preventing male osteoporosis, but given the observed side effects on liver, kidney, and prostate weights, it requires further investigation."],["dc.description.sponsorship"," Deutsche Forschungsgemeinschaft http://dx.doi.org/10.13039/501100001659"],["dc.description.sponsorship"," Georg-August-Universität Göttingen 501100003385"],["dc.identifier.doi","10.1007/s40618-022-01865-9"],["dc.identifier.pii","1865"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113421"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1720-8386"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","A combined treatment with selective androgen and estrogen receptor modulators prevents bone loss in orchiectomized rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Endocrinology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Saul, Dominik"],["dc.contributor.author","Hohl, Friederike Eva"],["dc.contributor.author","Franz, Max Konrad"],["dc.contributor.author","Meyer, Ilka"],["dc.contributor.author","Taudien, Stefan"],["dc.contributor.author","Roch, Paul Jonathan"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Komrakova, Marina"],["dc.date.accessioned","2021-08-12T07:45:42Z"],["dc.date.available","2021-08-12T07:45:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Background In previous studies, we reported the beneficial impact of two lipoxygenase-inhibitors, Baicalein and Zileuton, on osteoporotic bone in a postmenopausal rat model. Whereas subcutaneous Baicalein predominantly improved cortical bone, Zileuton enhanced vertebral and femoral trabecular bone. In this study, we aimed to reveal whether the oral administration of Baicalein caused similar effects on bone and whether a combined administration of Baicalein and Zileuton could act synergistically to ameliorate the formerly reported effects in the musculoskeletal system. Methods We treated ovariectomized (OVX) female Sprague-Dawley rats either with Baicalein (10mg/kg BW), Zileuton (10mg/kg BW) or a combination of both (each 10mg/kg BW) for 13 weeks and compared with untreated OVX and NON-OVX groups (n=12-16 rats per group). Lumbar vertebral bodies and femora were analyzed. Tibiae were osteotomized, plate-stabilized (at week 8 after OVX) and likewise analyzed by biomechanical, histological, micro-computed tomographical and ashing tests. The skeletal muscle structure was analyzed. Results Oral administration of Baicalein did not confirm the reported favorable cortical effects in neither vertebra nor femur. Zileuton showed a beneficial effect on trabecular vertebra, while the femur was negatively affected. Callus formation was enhanced by all treatments; however, its density and biomechanical properties were unaltered. Lipoxygenase inhibition did not show a beneficial effect on skeletal muscle. The combination therapy did not ameliorate OVX-induced osteoporosis but induced even more bone loss. Conclusions The preventive anti-osteoporotic treatments with two lipoxygenase inhibitors applied either alone or in combination showed no benefit for the musculoskeletal system in estrogen deficient rats."],["dc.description.abstract","Background In previous studies, we reported the beneficial impact of two lipoxygenase-inhibitors, Baicalein and Zileuton, on osteoporotic bone in a postmenopausal rat model. Whereas subcutaneous Baicalein predominantly improved cortical bone, Zileuton enhanced vertebral and femoral trabecular bone. In this study, we aimed to reveal whether the oral administration of Baicalein caused similar effects on bone and whether a combined administration of Baicalein and Zileuton could act synergistically to ameliorate the formerly reported effects in the musculoskeletal system. Methods We treated ovariectomized (OVX) female Sprague-Dawley rats either with Baicalein (10mg/kg BW), Zileuton (10mg/kg BW) or a combination of both (each 10mg/kg BW) for 13 weeks and compared with untreated OVX and NON-OVX groups (n=12-16 rats per group). Lumbar vertebral bodies and femora were analyzed. Tibiae were osteotomized, plate-stabilized (at week 8 after OVX) and likewise analyzed by biomechanical, histological, micro-computed tomographical and ashing tests. The skeletal muscle structure was analyzed. Results Oral administration of Baicalein did not confirm the reported favorable cortical effects in neither vertebra nor femur. Zileuton showed a beneficial effect on trabecular vertebra, while the femur was negatively affected. Callus formation was enhanced by all treatments; however, its density and biomechanical properties were unaltered. Lipoxygenase inhibition did not show a beneficial effect on skeletal muscle. The combination therapy did not ameliorate OVX-induced osteoporosis but induced even more bone loss. Conclusions The preventive anti-osteoporotic treatments with two lipoxygenase inhibitors applied either alone or in combination showed no benefit for the musculoskeletal system in estrogen deficient rats."],["dc.identifier.doi","10.3389/fendo.2021.706504"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88533"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-2392"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Inhibition of Lipoxygenases Showed No Benefit for the Musculoskeletal System in Estrogen Deficient Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","6893137"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Nutrition and Metabolism"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","2016"],["dc.contributor.author","Hoffmann, Daniel B."],["dc.contributor.author","Griesel, Markus H."],["dc.contributor.author","Brockhusen, Bastian"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Menger, Bjoern"],["dc.contributor.author","Wassmann, Marco"],["dc.contributor.author","Stuermer, Klaus Michael"],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2019-07-09T11:42:06Z"],["dc.date.available","2019-07-09T11:42:06Z"],["dc.date.issued","2016"],["dc.description.abstract","Background. 8-Prenylnaringenin (8-PN) is the phytoestrogen with the highest affinity for estrogen receptor-𝛼� (ER-𝛼�), which is required to maintain BMD. The osteoprotective properties of 8-PN have been demonstrated previously in tibiae. We used a rat osteopenia model to perform the first investigation of 8-PN with whole-body vertical vibration (WBVV). Study Design. Ovariectomy was performed on 52 of 64 Sprague-Dawley rats. Five weeks after ovariectomy, one group received daily injections (sc) of 8-PN (1.77mg/kg) for 10 weeks; a second group was treated with both 8-PN and WBVV (twice a day, 15 min, 35Hz, amplitude 0.47 mm). Other groups received either onlyWBVV or no treatment. Methods.The rats were sacrificed 15 weeks after ovariectomy. Lumbar vertebrae and femora were removed for biomechanical and morphological assessment. Results. 8-PN at a cancer-safe dose did not cause fundamental improvements in osteoporotic bones. Treatmentwith 8-PN caused a slight increase in uterine wetweight. Combined therapy using WBVV and 8-PN showed no significant improvements in bone structure and biomechanical properties. Conclusion. We cannot confirm the osteoprotective effects of 8-PN at a cancer-safe dose in primary affected osteoporotic bones. Higher concentrations of 8-PN are not advisable for safety reasons. Adjunctive therapy with WBVV demonstrates no convincing effects on bones."],["dc.identifier.doi","10.1155/2016/6893137"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12873"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58593"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-0732"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effects of 8-Prenylnaringenin and Whole-Body Vibration Therapy on a Rat Model of Osteopenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","224"],["dc.bibliographiccitation.issue","03"],["dc.bibliographiccitation.journal","OP-JOURNAL"],["dc.bibliographiccitation.lastpage","230"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Oberthür, Swantje"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Schilling, Arndt"],["dc.contributor.author","Lehmann, Wolfgang"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Hoffmann, Daniel"],["dc.date.accessioned","2019-10-14T07:07:03Z"],["dc.date.available","2019-10-14T07:07:03Z"],["dc.date.issued","2018"],["dc.description.abstract","Zusammenfassung Atypische Femurfrakturen (AFF) stellen einen Sonderfall in der Alterstraumatologie dar und machen im Hinblick auf die Gesamtzahl der Femurfrakturen nur einen geringen Anteil aus. Im Gegensatz zur klassischen Fraktur des proximalen Femurs sind AFF subtrochantär bzw. im Schaftbereich lokalisiert, entstehen häufig ohne adäquates Unfallereignis und zeigen charakteristische Merkmale im Röntgenbild. In vielen Fällen kommt es zu einem bilateralen Auftreten von AFF. Klinisch besteht oftmals Tage bis Monate vor der Diagnose einer AFF ein Prodromalschmerz im entsprechenden Bein bzw. der Leistengegend. Durch die American Society for Bone and Mineral Research (ASBMR) wurden Haupt- und Nebenkriterien zur Definition einer atypischen Femurfraktur erstellt. Diese sollen die Diagnosestellung erleichtern. Zu den Hauptkriterium zählen u. a. die peri- oder endostale Verdickung der lateralen Kortikalis sowie das Fehlen einer Frakturtrümmerzone. Um eine Fraktur als AFF zu definieren, müssen mindestens 4 der 5 Hauptkriterien erfüllt sein. Es gibt Evidenz für eine Korrelation zwischen AFF und der (Langzeit-)Einnahme von Bisphosphonaten. Atypische Femurfrakturen können jedoch auch ohne Bisphosphonateinnahme auftreten. Ist eine AFF diagnostiziert, sollte die Bisphosphonattherapie pausiert werden. Für die Therapie unterscheidet man zwischen kompletter und inkompletter Fraktur. Komplette AFF werden operativ zumeist mit einer Marknagelosteosynthese stabilisiert. Inkomplette Frakturen können konservativ therapiert werden – es gibt jedoch eine hohe Versagerrate mit Progress in eine komplette Fraktur, sodass bei persistierenden Schmerzen eher die prophylaktische Marknagelosteosynthese empfohlen wird. Der Behandlungsverlauf nach bisphosphonatassoziierten AFF ist häufiger mit perioperativen Komplikationen vergesellschaftet als die Behandlung von „typischen“ Femurfrakturen. Somit ist die Kenntnis der Pathophysiologie und der Therapieoptionen der Schlüssel zur erfolgreichen Behandlung dieser Verletzung."],["dc.identifier.doi","10.1055/s-0043-117830"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62488"],["dc.language.iso","de"],["dc.relation.issn","0178-1715"],["dc.relation.issn","1439-2496"],["dc.title","Die atypische Femurfraktur als Sonderfall der Alterstraumatologie"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]